The domestic substitution of pharmaceutical equipment has accelerated, and the performance of pharmaceutical machinery companies may have new breakthroughs

In recent years, China's pharmaceutical market has maintained a growth rate that exceeds that of the global pharmaceutical market
.
According to statistics, from 2016 to 2019, the market size of China's pharmaceutical industry has increased from 1,329.
4 billion yuan to 1,640.
7 billion yuan, with an average annual compound growth rate of 7.
26%
.
Following this trend, the market size of China's pharmaceutical industry is expected to reach 1922 billion yuan in 2021
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) It is worth noting that the current rapid growth of the pharmaceutical industry's market scale has also promoted the development of the pharmaceutical equipment industry, which is closely related to the pharmaceutical industry, to a certain extent
.
It is understood that the performance of many pharmaceutical equipment companies has doubled
.
For example, Chutian Technology’s third quarterly report for 2021 revealed that in the first three quarters, it created operating income of 3.
682 billion yuan, an increase of 67.
24% year-on-year, and achieved a net profit of 401 million yuan, an increase of 723.
53% year-on-year
.
In addition, in the first half of this year, Tofflon also achieved operating income of 1.
81 billion yuan, a year-on-year increase of 52.
22%; while Xinlai's profit was about 67.
89 million yuan, a year-on-year increase of 101.
1%
.
From an overall point of view, most of the company's net profit growth is related to the high level of prosperity in the pharmaceutical industry
.
For example, during the reporting period of Chutian Technology, new orders increased by 98% compared with the same period last year; it is reported that the pharmaceutical equipment segment revenue and orders in the first three quarters have accounted for about 40% of the company's share
.
Xinlai Yingcai also mentioned in the performance forecast that benefiting from the localization trend of semiconductors and the rapid expansion of domestic vaccine and pharmaceutical manufacturers, the company's biomedical sector business has grown rapidly.
.
.
At present, under the background of the rapid development of the pharmaceutical industry , The demand for pharmaceutical equipment is strong, and it has become a consensus in the industry that it is continuing to drive the growth of the performance of related companies
.
The industry believes that under this background, a new round of prosperity in the pharmaceutical equipment industry has arrived, and China's pharmaceutical equipment industry will also begin to accelerate its transformation and upgrading
.
According to the author’s understanding, in fact, the R&D investment of domestic pharmaceutical equipment companies represented by Teflon and Chutian Technology is indeed steadily increasing.
While product performance is improving, the business is also moving towards a diverse and intelligent overall solution provider.
In the direction of
.
It is worth mentioning that, with the popularization of artificial intelligence and industry 4.
0, and the accelerated transformation and upgrading of the pharmaceutical industry, the industry expects that the demand for automated, informatized, and intelligent high-end pharmaceutical equipment will gradually be strong
.
In the context of local pharmaceutical machinery companies continue to increase R&D investment, strive to break the import monopoly, and launch new products and new technologies, domestic pharmaceutical equipment is expected to accelerate the pace of import substitution
.
According to the author’s understanding, in recent years, domestic pharmaceutical equipment companies have upgraded from single machines to overall solutions, continued to increase R&D investment, and continued to improve product value-added and quality.
Domestic pharmaceutical equipment has begun to accelerate from low-end to mid-to-high-end.
The proportion of high-end products of large enterprises has also increased
.
Some research reports have shown that after ten years of industrial chain development, domestic pharmaceutical equipment companies have gradually become a subdivision of China's high-end manufacturing, domestic substitution has accelerated, export overseas business has grown rapidly, and the industry has gradually faded away from the cyclical nature and ushered in a long-term period.
Grow
.
In addition, industry data shows that the average annual growth rate of the total export delivery value of China's pharmaceutical equipment industry has reached 23.
075%
.
The industry predicts that as the concentration of the domestic pharmaceutical equipment industry continues to increase, the added value of products continues to increase, and the export volume is expected to continue to grow
.
In the future, domestically produced substitutes will promote performance improvement very much
.
However, it should be noted that while seeing the huge potential of the import substitution market, local pharmaceutical machinery companies also need to speed up to solve some of the bottlenecks that still exist in the pharmaceutical equipment industry
.
If in order to further narrow the gap between domestic equipment and technology and realize the import substitution of domestic pharmaceutical equipment, pharmaceutical equipment companies still need to continuously strengthen equipment innovation and technological research and development, improve service levels, and create higher-quality products to realize domestic medium and high-level pharmaceutical equipment.
The technical level is further improved, and the market competitiveness is continuously enhanced
.